Ofatumumab vs Rituximab in Relapsed or Refractory DLBCL

• Research type

  Research Study

• Full title

  Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL

• IRAS ID

  15472

• Sponsor organisation

  GlaxoSmithKline UK

• Eudract number

  2009-009256-20

• ISRCTN Number

  N/A

• Research summary

  N/A

• REC name

  East Midlands - Leicester Central Research Ethics Committee

• REC reference

  09/H0406/106

• Date of REC Opinion

  13 Nov 2009

• REC opinion

  Further Information Favourable Opinion